Aktionsplan Paradigm Biopharmaceuticals Limited
Erweiterter Zeitplan
Einfaches Diagramm
Über das Unternehmen Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.Industry | Biotechnology |
---|---|
Sector | Health Care |
Валюта | usd |
Валюта отчета | aud |
Сайт | https://www.paradigmbiopharma.com |
Цена ао | 0.3807 |
Preisänderung pro Tag: | 0% (0.3807) |
---|---|
Preisänderung pro Woche: | 0% (0.3807) |
Preisänderung pro Monat: | 0% (0.3807) |
Preisänderung über 3 Monate: | +170.96% (0.1405) |
Preisänderung über sechs Monate: | +231.91% (0.1147) |
Preisänderung pro Jahr: | +63.25% (0.2332) |
Preisänderung über 3 Jahre: | -54.93% (0.8446) |
Preisänderung über 5 Jahre: | -83.87% (2.36) |
Preisänderung seit Jahresbeginn: | +170.96% (0.1405) |
|
Unterschätzung
|
Effizienz
|
|||||||||||||||||||||||||||||||||||||
Dividenden
|
Pflicht
|
Wachstumsimpuls
|
Institutionen | Volumen | Aktie, % |
---|---|---|
Vanguard International Stock Index-Total Intl Stock Indx | 3456896 | 0.99 |
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund | 2117667 | 0.6 |
Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index | 1055062 | 0.3 |
Vanguard International Stock Index-Pacific Stock Index | 392059 | 0.11 |
SPDR Portfolio Developed World ex-US ETF | 169911 | 0.05 |
SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF | 105574 | 0.03 |
Vanguard Intl Equity Index - Total World Stock Index Fd | 71921 | 0.02 |
DFA Asia Pacific Small Company Series | 59638 | 0.02 |
Vanguard World Fund-Vanguard ESG International Stock ETF | 43440 | 0.01 |
Aufsicht | Berufsbezeichnung | Zahlung | Geburtsjahr |
---|---|---|---|
Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTC | Founder, MD & Executive Chairman | 1.17M | 1959 (66 Jahre) |
Dr. Donna L. Skerrett M.D., MS | Chief Medical Officer and Executive Director | 843.69k | 1957 (68 Jahre) |
Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. | Company Secretary & CFO | N/A | |
Dr. Ravi Krishnan | Chief Scientific Officer | N/A | |
Mr. Simon White | Director of Investor Relations | N/A | |
Dr. Michael Imperiale | Global Head of Drug Safety & MPS | N/A | |
Ms. Beverley Huttmann | Commercial Head | N/A | |
Ms. Michelle Coffey | Global Head of Regulatory Affairs | N/A | |
Dr. Mukesh Ahuja | Global Clinical Head of OA | N/A |
Adresse: Australia, Melbourne, 500 Collins Street - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.paradigmbiopharma.com
Webseite: https://www.paradigmbiopharma.com